GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)
Clinically meaningful improvement of 25 ETDRS letters equivalent versus nadir of BCVA in GS010-treated eyes at 96 weeks Results coherent…